Wellington Shields & Co. LLC Sells 368 Shares of Novo Nordisk A/S (NYSE:NVO)

Wellington Shields & Co. LLC lessened its position in Novo Nordisk A/S (NYSE:NVO) by 20.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,432 shares of the company’s stock after selling 368 shares during the period. Wellington Shields & Co. LLC’s holdings in Novo Nordisk A/S were worth $123,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Natixis Advisors LLC grew its holdings in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC grew its holdings in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after purchasing an additional 30,420 shares in the last quarter. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $86,000. Finally, Talbot Financial LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $4,066,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $77.22 on Friday. Novo Nordisk A/S has a 1-year low of $73.80 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The business has a fifty day moving average price of $83.95 and a 200-day moving average price of $103.24. The company has a market capitalization of $346.54 billion, a PE ratio of 23.47, a PEG ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 47.72%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on NVO shares. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.